Surface Oncology, Inc.
SURF · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.18 | 0.05 | 0.04 |
| FCF Yield | -37.01% | -55.36% | -44.39% | -30.75% |
| EV / EBITDA | -1.85 | -3.72 | -1.88 | -2.40 |
| Quality | ||||
| ROIC | -43.71% | -16.14% | -14.27% | -13.72% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 1.19 | 1.02 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -30.59% | -30.46% | -21.94% | -8.24% |
| Free Cash Flow Growth | 16.68% | -6.40% | -16.73% | -521.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | -1.43 | -0.18 | 0.39 |
| Interest Coverage | -8.25 | -21.10 | -142.17 | -27.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |